Myasthenia gravis is an autoimmune neuromuscular disease leading to fluctuating muscle weakness and fatigability. It is an autoimmune disorder, in which weakness is caused by circulating antibodies that inhibit the excitatory effects of the neurotransmitter acetylcholine on neuromuscular junctions. Muscular fatigue is often seen and MG is associated with ocular problems, and speech, swallowing, and breathing can be affected. Myasthenia Gravis is treated medically with acetylcholinesterase inhibitors or immunosuppressants, and in selected cases, thymectomy. MG is associated with other auto-immune conditions, including thyroid disease, lupus, and diabetes. Animal model studies are ongoing and, according to the Scandinavian Journal of Immunology in 2010, a study demonstrated that hMSC (mesenchymal stem cells) treatment was therapeutically useful in autoimmune myasthenia gravis mice, and the underlying mechanism may relate with their immunomodulatory potential.
Human research is ongoing to evaluate the effects of stem cells on auto-immune conditions.
CELL SURGICAL NETWORK has developed a specific SVF deployment protocol that attempts to utilize the potential immune-modulatory and regenerative properties of SVF (rich in mesenchymal stem cells and growth factors) to mitigate symptoms of Myasthenia Gravis. SVF is deployed systemically and may require repeat dosing. This is done as an outpatient at the time of SVF harvesting and procurement. The entire cellular surgical procedure takes approximately three hours.
We care about our Myasthenia Gravis patients at the Cell Surgical Network and take pride in the time we provide to our patients to deploy the best protocols to help our patients achieve their goals. By filling out Candidate Application, we will answer the questions and concerns you may have about Cell Surgical Network protocols for Myasthenia Gravis.